75 results
6-K
EX-99.1
SPRC
SciSparc Ltd
9 Mar 22
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
10:59am
Exhibit 99.1
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
TEL AVIV, Israel, March 8, 2022 … Medicine Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0) to explore the potential for the creation of innovative compounds in the psychedelic area
6-K
EX-99.1
SPRC
SciSparc Ltd
11 Feb 21
SciSparc Announces Rebranding and Business Updates
10:01am
, which will follow after we enter into a distribution agreement."
The new branding is in line with the company's innovative and advanced technology … -clinical programs were renamed as follows:
Clinical programs:
SCI-110 - An innovative and proprietary drug candidate platform based on Delta-9
6-K
EX-99.1
SPRC
SciSparc Ltd
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
on the development of innovative medical device hydrogels delivered in the form of nasal sprays (“Polyrizon”).
As part of the collaboration, the two companies … drug delivery technology to target the central nervous system.
SciSparc’ s top-tier investigational drug candidate, SCI-160, is an innovative
6-K
EX-99.1
SPRC
SciSparc Ltd
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
innovative treatments with the ability to change millions of lives worldwide.”
The trial, titled “Phase IIa Open Label Trial to Evaluate the Safety … ), and CannAmide™, the Company’s proprietary formulation of Palmitoylethanolamide (PEA).
SCI-110 is one of the innovative combinations of SciSparc
6-K
EX-99.1
SPRC
SciSparc Ltd
10 Mar 22
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
10:16am
of milestones agreed upon in the agreement. MitoCareX Bio’s innovative research will partly build upon successful proof-of-concept experiments performed … drugs for cancers and other life-threatening conditions and in investing in new innovative research opportunities to potentially further expand
6-K
4n7ickmr
9 Mar 22
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
10:59am
6-K
EX-99.1
kjgml 3lf9oueouz6g
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
6-K
EX-99.1
xcyxq2cc3
24 Feb 21
SciSparc Corporate Presentation February 2021
9:27am
6-K
EX-99.1
niwuw pk5oq
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
gsrd35t1glsbtk3
11 May 22
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
1:58pm
6-K
EX-99.1
dnbeexch3r26yw9y
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
EX-99.1
phtqz2zsh90a
17 Feb 21
Report of Foreign Private Issuer
8:35am
6-K
EX-99.1
bicor4b
16 Sep 20
Developing cannabinoid based pharmaceuticals Corporate Presentation • September 2020
7:11am
FWP
2yt9q36 i67
5 Nov 20
Free writing prospectus
5:11pm
FWP
dwdn8
21 Oct 20
Free writing prospectus
7:26am
6-K
EX-99.1
3yok 5vgacsm687l3
9 Jun 22
SciSparc’s Board of Directors Provides Strategic Decision
8:38am
6-K
EX-99.1
vfipsnmb2nmj 7yyp33t
29 Feb 24
Report of Foreign Private Issuer
9:07am
6-K
EX-99.2
2uan8azr
2 Dec 20
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
9:25am
6-K
EX-99.1
xr4m i49xhvii69vacyj
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
h2uoevh1x1jbe nf9
5 Jan 21
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada
9:12am